Clinical Trial Update: Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008) [Phase 3]

View source ↗

Summary

Phase 3 trial update reporting safety and immunogenicity results for the V116 pneumococcal vaccine in adults at increased risk for pneumococcal disease; results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infection

Drugs mentioned

• V116

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Pneumococcal Infection | Phase 3 | Status: COMPLETED | Results posted: 2025-02-26